3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
Azacitidine
38
Cytarabine
37
venetoclax
35
fludarabine
28
Cyclophosphamide
21
Daunorubicin
18
fludarabine phosphate
17
Decitabine
17
Specimen Handling
15
Tacrolimus
14
Injections
13
Busulfan
13
Biopsy
12
Melphalan
11
Granulocyte Colony-Stimulating Factor
11
CPX-351
11
Mycophenolic Acid
10
Idarubicin
10
Stem Cell Transplantation
9
Whole-Body Irradiation
8
Etoposide
8
decitabine and cedazuridine drug combination
7
Thiotepa
7
Mitoxantrone
7
enasidenib
6
Peripheral Blood Stem Cell Transplantation
6
Methotrexate
6
ivosidenib
5
gilteritinib
5
Gemtuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Myeloid, Acute
×
lentiviral minigene vaccine of COVID-19 coronavirus
×
Clear all
NCT01686334
2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2
Active not recruiting
130 enrolled